New Trials Gives Hope for Tuberculosis Vaccine

APRIL 01, 2004
Susan Farley

A new vaccine for tuberculosis (TB) will soon undergo the first phase of human safety testing. The first of its kind to be tested in the United States in the last 60 years, the new vaccine combines 2 TB proteins that stimulate a strong response by the human immune system. Researchers were able to identify these proteins from blood samples of people who never got TB despite being infected with Mycobacterium tuberculosis bacteria. These proteins were fused using recombinant DNA technology and then combined with substances that would further boost an immune system's response to the vaccine. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, remarked, "This candidate vaccine ... offers hope for reducing the burden of a disease that claims approximately 2 million lives each year."



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.